Archives

19
May

Marker Identifies Breast Cancer Patients Likely to Respond to Tamoxifen

ER positive breast cancer patients whose tumors have active protein Stat5 have increased likelihood of responding to anti-estrogen therapy PHILADELPHIA—Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears …

22
Feb

Prolactin Blocks Oncogene Associated with Poor Prognosis in Breast Cancer

Researchers from the Kimmel Cancer Center at Jefferson have found a mechanism by which a hormone responsible for milk production blocks an oncogene that makes breast cancer more aggressive. Publishing in the journal Cancer Research, the researchers discovered that prolactin, a pituitary hormone that normally stimulates breast development and milk production, in fact reduces levels …

14
Apr

Jefferson’s Kimmel Cancer Center Researchers Receive $6.7 million Grant from Susan G. Komen for the Cure

Researchers from the Kimmel Cancer Center at Jefferson were awarded a Susan G. Komen for the Cure Promise Grant of almost $6.7 million for five years for continued breast cancer research. The project represents a multidisciplinary team of scientists from a consortium that also includes Walter Reed Army Medical Center and DecisionQ Inc. in Washington …

24
Mar

Jefferson Breast Cancer Researcher to Receive PA Income Tax Check-Off Grant

Hallgeir Rui, M.D., Ph.D, a professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and Jefferson’s Kimmel Cancer Center, is one of three recipients of the Income Tax Check-Off for Breast & Cervical Cancer Research grants this year. The $50,000 award will be used to conduct research to understand what causes the …